➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Express Scripts
McKinsey
McKesson
Harvard Business School

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,777,423


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,777,423 protect, and when does it expire?

Patent 6,777,423 protects SPIRIVA and is included in one NDA.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-five patent family members in forty-six countries.

Summary for Patent: 6,777,423
Title: Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Abstract:Crystalline monohydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl) oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4 ]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
Inventor(s): Banholzer; Rolf (Stuttgart, DE), Sieger; Peter (Mittelbiberach, DE), Kulinna; Christian (Mainz, DE), Trunk; Michael (Ingelheim, DE), Graulich; Manfred (Waldalgesheim, DE), Specht; Peter (Ober-Hilbersheim, DE), Meissner; Helmut (Ingelheim, DE), Mathes; Andreas (Ockenheim, DE)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:10/354,521
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,777,423
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 6,777,423

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,777,423

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 50 621Oct 12, 2000

International Family Members for US Patent 6,777,423

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1572 ⤷  Free Forever Trial
Argentina 034389 ⤷  Free Forever Trial
Argentina 068527 ⤷  Free Forever Trial
Austria 276253 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKinsey
AstraZeneca
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.